Jacques P Tremblay
Overview
Explore the profile of Jacques P Tremblay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
2407
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Happi Mbakam C, Roustant J, Rousseau J, Yameogo P, Lu Y, Bigot A, et al.
Front Med (Lausanne)
. 2023 Jun;
10:1128557.
PMID: 37305116
Duchenne muscular dystrophy is a rare and lethal hereditary disease responsible for progressive muscle wasting due to mutations in the gene. We used the CRISPR-Cas9 Prime editing technology to develop...
12.
Godbout K, Tremblay J
Cells
. 2023 Feb;
12(4).
PMID: 36831203
Gene therapy holds tremendous potential in the treatment of inherited diseases. Unlike traditional medicines, which only treat the symptoms, gene therapy has the potential to cure the disease by addressing...
13.
Yameogo P, Gerard C, Majeau N, Tremblay J
Gene Ther
. 2023 Feb;
30(7-8):612-619.
PMID: 36781946
Most Friedreich ataxia (FRDA) cases are caused by the elongation of the GAA repeat (GAAr) sequence in the first intron of the FXN gene, leading to a decrease of the...
14.
Yameogo P, Majeau N, Happi Mbakam C, Tremblay J
PLoS One
. 2023 Jan;
18(1):e0280353.
PMID: 36656806
The small size of CjCas9 can make easier its vectorization for in vivo gene therapy. However, compared to the SpCas9, the CjCas9 is, in general, less efficient to generate indels...
15.
Happi Mbakam C, Rousseau J, Lu Y, Bigot A, Mamchaoui K, Mouly V, et al.
Mol Ther Nucleic Acids
. 2022 Nov;
30:272-285.
PMID: 36320324
Duchenne muscular dystrophy is a severe debilitating genetic disease caused by different mutations in the gene leading to the absence of dystrophin protein under the sarcolemma. We used CRISPR-Cas9 prime...
16.
Godbout K, Tremblay J
Pharmaceutics
. 2022 Oct;
14(10).
PMID: 36297564
Gene therapy holds great promise in the treatment of genetic diseases. It is now possible to make DNA modifications using the CRISPR system. However, a major problem remains: the delivery...
17.
Gerard C, Archambault A, Bouchard C, Tremblay J
Behav Brain Res
. 2022 Sep;
436:114107.
PMID: 36089099
Friedreich Ataxia (FRDA) is a genetic disease caused by an expended GAA repeat in the FXN gene leading to a reduction in frataxin protein production. Frataxin is an essential protein...
18.
Bchetnia M, Dionne Gagne R, Powell J, Morin C, McCuaig C, Duperee A, et al.
CRISPR J
. 2022 Jul;
5(4):586-597.
PMID: 35862015
Epidermolysis bullosa simplex (EBS) is a rare mechanobullous disease caused by dominant-negative mutations in either keratin 5 () or keratin 14 () genes. Until now, there is no cure for...
19.
Happi Mbakam C, Rousseau J, Tremblay G, Yameogo P, Tremblay J
Int J Mol Sci
. 2022 Jun;
23(11).
PMID: 35682838
The Prime editing technique derived from the CRISPR/Cas9 discovery permits the modification of selected nucleotides in a specific gene. We used it to insert specific point mutations in exons 9,...
20.
Majeau N, Fortin-Archambault A, Gerard C, Rousseau J, Yameogo P, Tremblay J
Mol Ther
. 2022 May;
30(7):2429-2442.
PMID: 35619556
Extracellular vesicles (EVs) mediate intercellular biomolecule exchanges in the body, making them promising delivery vehicles for therapeutic cargo. Genetic engineering by the CRISPR system is an interesting therapeutic avenue for...